Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Automatic Data Processing Inc (ADP) vs Amgen, Inc. (AMGN) Price & Performance

Automatic Data Processing IncTrade
Amgen, Inc.Trade

Price performance (Past 24H)

Key statistics

Automatic Data Processing Inc vs Amgen, Inc. — how do they compare? Automatic Data Processing Inc trades at $269.97 (market cap $107.69B), while Amgen, Inc. trades at $412.15 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 2.1× Automatic Data Processing Inc's market cap, and Automatic Data Processing Inc pays the higher dividend (2.51%). Which is the better fit depends on your goals.

ADPAMGN
Market Cap
$107.69B$224.14B
Sector
IndustrialsHealth
52-Week High
$309.03$417.20
52-Week Low
$188.79$271.18
Enterprise Value
$108.73B$267.45B
Dividend Yield
2.51%2.43%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Automatic Data Processing Inc

ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.

Read more on ADP

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN